Rethinking Clinical Trials

APRIL 16, 2025

Dr. Sanjit Jolly In this Friday’s PCT Grand Rounds, Sanjit Jolly of McMaster University will present “Colchicine and Spironolactone Post-MI: A Review of the Late-Breaking Results of the CLEAR OASIS 9 Trial.” The Grand Rounds session will be held on Friday, April 18, 2025, at 1:00 pm eastern. Jolly is an interventional cardiologist at Hamilton Health Sciences and the Stuart Connolly Chair in Cardiology and a professor of medicine at McMaster University.

Cardiology 147

Cardiology Clinical Trials Clinical Trials Trials 147

Bio Pharma Dive

APRIL 16, 2025

Two studies published in Nature found stem cell-derived products can not only be safely transplanted into the brain, but also show promising — albeit unproven — signs of efficacy.

Research 311

Research Production 311

Pharmaceutical Technology

APRIL 16, 2025

The agreement is seen as a win for global health ahead of the US withdrawal from the WHO and amidst foreign aid cuts by the US government.

162

162

Bio Pharma Dive

APRIL 16, 2025

The biotech is developing an experimental drug for the most common of a family of disorders all caused by errors in glycosylation.

Drugs 252

Drugs Development 252

Speaker: Brian Richardson, Brian Richardson, Founder and CEO of Richardson Consulting Group

Let’s face it—most ethics and compliance trainings aren’t winning awards for engagement. But that doesn’t mean they can’t be effective, relevant, and maybe even enjoyable! Join expert Brian Richardson for a dynamic session on how to breathe new life into your ethics and compliance training programs. You’ll discover creative strategies to turn traditionally dry topics into meaningful learning experiences that resonate and drive real change.

Compliance

XTalks

APRIL 16, 2025

The FDA has authorized the marketing of CT-132, a prescription digital therapeutic (DTx) developed by Click Therapeutics for the preventive treatment of episodic migraine in adults. CT132 is the first FDA-cleared digital therapeutic for migraine prevention, expanding treatment options beyond conventional medications. It also aligns with the growing interest in software-based interventions.

Trials 59

Trials Marketing Development Regulation 59

Bio Pharma Dive

APRIL 16, 2025

The advisory committee, which met Tuesday for the first time since Robert F. Kennedy Jr. was sworn in as health secretary, also discussed the Texas measles outbreak.

241

241

Bio Pharma Dive

APRIL 16, 2025

The company’s board reiterated its recommendation to instead pursue an offer from SK Capital and Carlyle that’s worth about $29 million upfront.

241

241

Pharmaceutical Technology

APRIL 16, 2025

Glycomines Series C raise highlights investor confidence in the company amid pressure on the paediatric rare disease sector.

130

130

Bio Pharma Dive

APRIL 16, 2025

After a lengthy regulatory back-and-forth, Eisai and Biogen's Alzheimer's drug is on the market in Europe. Elsewhere, Sandoz is alleging Amgen's patent actions were anticompetitive.

Marketing 159

Marketing Drugs 159

Pharmaceutical Technology

APRIL 16, 2025

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide offerings.

Drugs 130

Drugs 130

Advertisement

Enhancing Transparency & Efficiency Throughout the Trial Lifecycle for AI Readiness

Trials

Pharma Times

APRIL 16, 2025

European Commission grants authorisation for Eisai and Biogen therapy

129

129

Pharmaceutical Technology

APRIL 16, 2025

Eisai and Biogen have received marketing authorisation from the European Commission (EC) for Leqembi (lecanemab) to treat Alzheimer's.

Marketing 130

Marketing 130

XTalks

APRIL 16, 2025

In this episode, Ayesha spoke with Marc Hedrick, MD, MBA, president and CEO of Plus Therapeutics, a company focused on developing a novel class of targeted radiotherapeutics. Prior to heading Plus Therapeutics, Dr. Hedrick served in a number of executive leadership roles including president, CEO and director at Cytori Therapeutics, and president and CEO of StemSource.

Life Science 59

Life Science Development Research Medicine 59

Pharmaceutical Technology

APRIL 16, 2025

Mural Oncology is halting development of its lead IL-2 therapy and enacting major layoffs after its second trial failure this year.

Trials 130

Trials Development 130

Speaker: Amie Phillips Pablo, VP, Corporate Compliance & Privacy Officer at Novo Nordisk

In today’s complex healthcare environment, navigating third-party relationships has become even more challenging—whether it’s vendor relationships, employee activities, or patient-facing interactions. Left unmanaged, these conflicts can compromise trust, regulatory compliance, and even organizational reputation. So, how can healthcare teams stay ahead?

Compliance

pharmaphorum

APRIL 16, 2025

The Joint Clinical Assessment (JCA) framework took effect on 12th January 2025, and its impact is top of mind among pharma innovators today.

108

108

Pharmaceutical Technology

APRIL 16, 2025

Boehringer and Cue Biopharma have entered a strategic research partnership and licence agreement for the latters CUE-501.

Development 130

Development Research 130

pharmaphorum

APRIL 16, 2025

Click Therapeutics' digital therapeutic (DTx) for migraine prevention has been cleared by the FDA, becoming the first treatment of its type in the US.

94

94

Pharmaceutical Technology

APRIL 16, 2025

AD is a growing market with an impressive pipeline of new products from current and future players in the field.

Marketing 130

Marketing Production 130

Advertisement

Download this comprehensive guide to AI and ML in the R&D Laboratory Setting.

Life Science

Drug Channels

APRIL 16, 2025

Drug Channels Institutes (DCIs) latest analysis reveals that PBM-affiliated specialty pharmacies continue to dominate the dispensing of specialty drugs. DCI has identified nearly 1,900 dispensing locations with specialty pharmacy accreditation. Below, we share DCIs latest analysis of the top 15 specialty pharmacies, including updated market shares and revenue estimates.

Pharmacy 40

Pharmacy Marketing Drugs 40

Pharma Times

APRIL 16, 2025

New real-world data reinforce treatment benefit

82

82

pharmaphorum

APRIL 16, 2025

Access to de-identified NHS patient data by researchers based in China is not a security concern, according to UK Biobank.

Biobanking 66

Biobanking Research 66

Pharmaceutical Commerce

APRIL 16, 2025

Will Robinson, program director, LogiPharma, explains how artificial intelligence and sustainability are driving a clear shift in priorities across the pharmaceutical supply chain.

52

52

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

pharmaphorum

APRIL 16, 2025

Discover the transformative potential of digital health and AI in providing cutting-edge care for rare diseases like Lysosomal Storage Disorders (LSDs). Learn about the latest advancements and innovations in rare disease management and early diagnosis.

59

59

Pharmaceutical Commerce

APRIL 16, 2025

The new firmwith 13 manufacturing facilities spanning France, Sweden, and Spainwill support the pharma supply chain through to commercialization.

Manufacturing 52

Manufacturing 52

pharmaphorum

APRIL 16, 2025

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Sonia A. Veluchamy, CEO and co-founder of Celegence, a company dedicated to improving patient outcomes through intelligent regulatory compliance.

Compliance 52

Compliance 52

Pharmaceutical Commerce

APRIL 16, 2025

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Rachel Thorpe, executive director at the Otsuka Patient Assistance Foundation, emphasizes the importance of the separation of core business and foundation, the value of patient empowerment, and the impact of digital innovation.

52

52

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Medicine

pharmaphorum

APRIL 16, 2025

TPD & Induced Proximity Pharma Partnering Summit Sara.

52

52

Pharmaceutical Technology

APRIL 16, 2025

Our editorial team dissects the latest developments in the ongoing story of how evolving US tariffs could impact the pharmaceutical sector.

Development 130

Development 130

pharmaphorum

APRIL 16, 2025

The EU has approved Eisai and Biogen's Leqembi for a subset of patients with early-stage Alzheimer's disease, more than two years after it was filed.

Drugs 51

Drugs 51

Pharmaceutical Technology

APRIL 16, 2025

Irish medical and pharmaceutical exports to the US have seen a surge, with a year-on-year increase above 450% in February 2025.

130

130

Advertisement

Clinical Supply